Canget BioTekpharma LLC
CHINESE (中文版)


Close Window
ANNOUNCEMENT:

Agreement with Pinot Bio to Develop Antibody-Drug Conjugates Signed

Buffalo, NY— September 15, 2021 — Today, Canget BioTekpharma and PinotBio announced the signing of an agreement to develop new products that combine technologies from both companies to improve outcomes for patients with resistant cancers.

The new product will deliver high payload to drug resistant cancers.

Please see News and Publications for more details.

Introduction
Canget BioTekpharma, LLC (Canget) is a biotech and biopharma company, and was spun off in 2012 from Roswell Park Cancer Institute (RPCI, Buffalo, New York). Canget focuses on development of novel, cancer-targeting anticancer agents that exhibit low toxicity to normal tissue and high efficacy to cancer.

RPCI (www.roswellpark.org) as a partner of Canget, is the first cancer institution (founded in 1898) in the history of the United States and is a National Cancer Institute (NCI)-designated Comprehensive Cancer Center, which unites cancer prevention, treatment and patient care, cancer research and education into one.
Challenge
Drug toxicity with limited antitumor efficacy, cancer resistance to treatment and cancer metastasis are the major challenge in cancer management. Therefore, development of novel, cancer-targeting agents that address these challenges would be of the upmost importance to win the war against cancer.
Mission
To dramatically improve cancer patient survival times and survival rates through eliminating cancer cell drug resistance and tumor metastasis/relapse by providing highly effective, low toxic and cancer-targeting anticancer agents for cancer patients.
Vision
Establish a best practice under a good enterprise culture in the company where the success of Canget BioTekpharma, LLC (Canget) in innovation and drug development could lead to a significant improvement of quality of life and life span for cancer patients. Meanwhile, the prosperity of Canget could give the company an ability to allocate deserved compensations to owners, employees, collaborators, and other contributors, while contributing local communities and national economies as well as making returns to the society through various types of charitable activities.



Canget BioTekpharma Company Copyright. All rights reserved.